Project selected as US$4.4 million grant recipient by GHIT Fund
The fight against dengue continues with the latest joint research project between Chugai Pharmaceutical Co., Ltd. and the Agency for Science, Technology and Research, Singapore (A*STAR).
Dengue infects 390 million people annually and kills tens of thousands, with a recent study highlighting that nearly half the world鈥檚 population could be at risk of catching dengue by 2050.
In 2018 alone, a total of 3,285 dengue cases were reported in Singapore with five deaths by dengue last year. Dengue remains an endemic threat in Singapore and many developing countries.
This project seeks to create a new antibody drug against the dengue virus through the collaboration between Chugai Pharmabody Research, a research center of the Chugai Group in Singapore, and A*STAR鈥檚 Singapore Immunology Network (SIgN).
Through the support of the Global Health Innovative Technology Fund (GHIT Fund) with an approximately US$4.4 million grant, this project is set to combat the global burden of dengue and fight against neglected tropical diseases in developing countries.
Click here for the complete issue.